Skip to main content

Table 2 Regulation of the 52 most frequently detected miRNAs in CSF of patients with dementia

From: miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

miRNA

NAD

Ncontrol

MAD (range)

Mcontrol (range)

FC

p

miR-15a-5p

10

10

1.20 (0.63–4.22)

0.83 (0.52–1.01)

1.44

0.005

miR-29c-3p

10

10

0.81 (0.47–1.55)

1.33 (0.75–1.78)

0.60

0.009

let-7i-5p

10

10

1.31 (0.67–3.23)

0.85 (0.27–1.27)

1.54

0.019

miR-22-3p

10

9

0.83 (0.20–1.75)

1.35 (0.83–2.01)

0.62

n.s.

miR-24-3p

9

10

0.91 (0.19–1.23)

1.17 (0.81–1.94)

0.78

n.s.

miR-185-5p

10

9

1.35 (0.39–5.13)

0.62 (0.30–1.45)

2.16

n.s.

miR-27b-3p

10

10

0.95 (0.49–1.48)

1.21 (0.63–1.87)

0.78

n.s.

miR-142-3p

9

9

1.19 (0.27–4.31)

0.86 (0.26–1.83)

1.38

n.s.

let-7 g-5p

10

10

1.09 (0.55–2.75)

0.79 (0.39–2.19)

1.37

n.s.

miR-23a-3p

10

10

0.92 (0.53–1.55)

1.11 (0.62–2.04)

0.82

n.s.

miR-23b-3p

10

10

1.00 (0.38–1.24)

1.05 (0.60–2.55)

0.94

n.s.

miR-130a-3p

10

10

0.82 (0.41–1.56)

1.22 (0.42–2.13)

0.67

n.s.

let-7c-5p

10

10

0.88 (0.37–2.21)

1.15 (0.35–3.09)

0.76

n.s.

miR-150-5p

10

9

0.89 (0.23–5.44)

0.82 (0.37–1.68)

1.09

n.s.

miR-361-5p

9

9

0.95 (0.47–1.32)

1.00 (0.70–1.51)

0.94

n.s.

miR-25-3p

10

9

1.00 (0.36–5.49)

0.87 (0.34–1.77)

1.14

n.s.

miR-221-3p

10

10

1.68 (0.15–3.04)

1.22 (0.15–1.70)

1.38

n.s.

miR-29a-3p

10

10

0.96 (0.72–1.30)

1.01 (0.71–1.71)

0.94

n.s.

miR-30a-5p

10

10

1.32 (0.20–2.91)

1.12 (0.37–1.91)

1.17

n.s.

miR-10b-5p

9

10

0.90 (0.26–5.08)

1.04 (0.21–1.70)

0.86

n.s.

let-7a-5p

10

10

0.80 (0.29–2.58)

1.14 (0.65–3.49)

0.70

n.s.

miR-125b-5p

10

10

0.85 (0.62–1.53)

0.98 (0.69–2.77)

0.87

n.s.

miR-16-5p

10

10

0.96 (0.05–9.45)

0.98 (0.56–1.47)

0.98

n.s.

miR-424-5p

10

10

1.19 (0.35–3.38)

0.72 (0.47–2.38)

1.65

n.s.

miR-143-3p

10

10

1.04 (0.45–1.48)

0.92 (0.69–2.32)

1.12

n.s.

miR-19a-3p

9

10

1.14 (0.21–3.68)

1.15 (0.65–1.49)

0.99

n.s.

miR-124-3p

10

9

1.31 (0.26–2.73)

1.21 (0.32–2.08)

1.08

n.s.

let-7b-5p

10

10

1.03 (0.31–3.50)

0.83 (0.45–3.39)

1.23

n.s.

miR-146a-5p

9

10

1.37 (0.23–2.40)

0.91 (0.20–2.69)

1.50

n.s.

let-7d-3p

9

10

1.02 (0.54–1.89)

1.33 (0.62–1.83)

0.76

n.s.

miR-125a-5p

10

9

1.21 (0.32–2.96)

0.71 (0.29–2.68)

1.69

n.s.

miR-27a-3p

9

10

1.14 (0.15–2.81)

1.29 (0.25–3.03)

0.88

n.s.

miR-30d-5p

10

10

1.16 (0.31–2.47)

1.15 (0.34–1.83)

1.01

n.s.

miR-99a-5p

10

10

0.98 (0.57–1.36)

1.07 (0.62–1.93)

0.91

n.s.

miR-145-5p

10

10

1.16 (0.30–1.73)

1.00 (0.47–2.05)

1.15

n.s.

miR-100-5p

10

10

0.92 (0.54–1.88)

1.07 (0.63–1.86)

0.85

n.s.

miR-223-3p

9

10

1.14 (0.86–2.74)

0.78 (0.22–4.81)

1.45

n.s.

miR-320a

10

10

0.94 (0.54–1.62)

1.05 (0.64–1.68)

0.90

n.s.

miR-497-5p

10

10

1.07 (0.51–1.72)

1.08 (0.64–1.81)

0.98

n.s.

miR-373-5p

9

10

1.10 (0.26–2.66)

1.11 (0.30–3.44)

0.98

n.s.

miR-204-5p

10

10

1.05 (0.07–2.30)

0.99 (0.47–2.28)

1.06

n.s.

miR-92a-3p

10

10

0.94 (0.70–3.69)

0.84 (0.47–2.17)

1.12

n.s.

miR-423-5p

10

10

1.11 (0.65–2.27)

0.78 (0.44–2.22)

1.42

n.s.

miR-19b-3p

10

10

1.08 (0.18–2.25)

1.20 (0.21–2.20)

0.90

n.s.

miR-9-5p

9

10

1.25 (0.50–1.97)

1.24 (0.24–3.11)

1.00

n.s.

miR-30c-5p

10

10

1.15 (0.20–2.57)

0.99 (0.37–2.38)

1.15

n.s.

miR-21-5p

10

10

0.89 (0.66–2.29)

1.06 (0.27–1.86)

0.83

n.s.

miR-34a-5p

10

9

0.99 (0.26–2.39)

1.06 (0.46–2.07)

0.94

n.s.

miR-101-3p

10

9

1.11 (0.37–1.48)

0.93 (0.56–2.64)

1.19

n.s.

miR-29b-3p

9

9

1.12 (0.31–1.76)

0.92 (0.49–2.02)

1.22

n.s.

miR-199a-3p

10

10

0.92 (0.58–3.40)

1.16 (0.39–1.67)

0.79

n.s.

miR-9-3p

10

10

1.13 (0.23–2.35)

1.02 (0.28–2.86)

1.09

n.s.

  1. N AD number of Alzheimer patients in which the miRNA was detected, N control number of control patients in which the miRNA was detected, M AD the median of relative expression levels among Alzheimer patients, M control median of relative expression levels among control patients, FC fold change of median values, p p-values of difference calculated by two-sided nonparametric Mann–Whitney test (not corrected for multiple testing), n.s. nonsignificant (p > 0.05)
Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us